Metsmall 500 SR (Metformin)

Product Overview

Metsmall 500 SR is an extended‑release formulation of Metformin marketed by Dr Reddy’s Laboratories Ltd. Each strip contains 30 tablets delivering 500 mg of Metformin per tablet. The product is available in pack sizes of 30, 60, and 90 tablets, with a delivery window of 6 to 15 days. It is classified under Diabetes Care and is intended for the management of Type 2 diabetes mellitus.

What is Metsmall 500 SR

Metsmall 500 SR (Metformin) belongs to the biguanide class of antidiabetic agents. The “SR” designation indicates a sustained‑release matrix that releases the active ingredient gradually over approximately 24 hours, allowing once‑daily dosing. This formulation helps maintain steady plasma concentrations, reduces gastrointestinal discomfort compared with immediate‑release Metformin, and supports better adherence.

Uses and Benefits

Metsmall 500 SR is prescribed alongside diet and exercise to improve glycemic control in adults with Type 2 diabetes. Clinical studies show that Metformin lowers fasting plasma glucose, reduces post‑prandial glucose spikes, and modestly decreases body weight. Additional benefits include improved insulin sensitivity, reduced hepatic glucose production, and potential cardiovascular risk reduction, as highlighted by NIH research on diabetes management.

How It Works

The drug acts primarily by inhibiting hepatic gluconeogenesis, decreasing intestinal glucose absorption, and enhancing peripheral insulin sensitivity. The sustained‑release design ensures a controlled release of Metformin, which maintains therapeutic levels throughout the day, minimizes peaks and troughs, and lowers the risk of dose‑related side effects.

Dosage Guidelines

Typical initiation is 500 mg once daily with the evening meal. The dose may be titrated upward by 500 mg weekly, up to a maximum of 2000 mg per day (four tablets), based on glycemic response and tolerability. Patients should swallow the tablet whole; crushing or chewing may compromise the extended‑release profile. Adjustments are recommended for patients with impaired renal function, using the FDA‑recommended eGFR thresholds.

Side Effects

Most adverse events are mild to moderate and involve the gastrointestinal system, such as nausea, diarrhea, abdominal discomfort, or metallic taste. Rare but serious side effects include lactic acidosis, particularly in patients with renal impairment, hepatic disease, or conditions predisposing to hypoxia. Monitoring renal function and educating patients about signs of lactic acidosis (e.g., unexplained fatigue, muscle pain, rapid breathing) are essential safety measures.

Warnings and Precautions

Before prescribing Metsmall 500 SR, clinicians should assess renal function, hepatic health, and risk of conditions that may increase lactic acidosis. The medication is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and in those undergoing scheduled contrast imaging with iodinated contrast agents. Pregnant or breastfeeding women should use only if clearly needed, and medical advice should be sought. For comprehensive guidance, refer to the FDA prescribing information.

Frequently Asked Questions

1. Can Metsmall 500 SR be taken with other diabetes medications? Yes, it is often combined with sulfonylureas, DPP‑4 inhibitors, or insulin, but dosage adjustments may be required to avoid hypoglycemia.
2. How long does it take to see a reduction in blood glucose levels? Most patients experience a measurable drop in fasting glucose within 1‑2 weeks, with maximal effect seen after 4‑6 weeks of consistent use.
3. Is weight loss common when using Metformin? Metformin is weight‑neutral or may cause modest weight loss, especially when combined with lifestyle modifications.
4. Do I need to monitor my kidney function regularly? Yes; renal function should be checked at least annually, or more frequently if there are risk factors for decline.
5. Can I drink alcohol while taking Metsmall 500 SR? Moderate alcohol intake is generally permissible, but excessive consumption increases the risk of lactic acidosis and should be avoided.

For more detailed information on diabetes care, visit the National Institutes of Health, Drugs.com, or the MedlinePlus resources. Always consult a healthcare professional before starting or changing any medication.

Related Products

• Razo (Rabeprazole)
• Morease-I Granules (Mebeverine/Ispaghula)
• Razo 10 mg (Rabeprazole)
• Omeprazole 40 mg (Generic)
• Omez 10 mg (Omeprazole)
• Omez 20 mg (Omeprazole)
• Omez 40 mg (Omeprazole)
• Omez (Omeprazole)
• Razo 20 mg (Rabeprazole)
• Omeprazole 10 mg (Generic)
• Omeprazole 20 mg (Generic)
• Salicylix SF 6% Cream (Salicylic Acid)